Stayble Therapeutics AB (OSTO:STABL) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Stayble Therapeutics AB's Free Cash Flow for the three months ended in Sep. 2024 was kr-4.46 Mil. Stayble Therapeutics AB's Revenue for the three months ended in Sep. 2024 was kr0.00 Mil. Therefore, Stayble Therapeutics AB's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Stayble Therapeutics AB's current FCF Yield % is -25.27%.

The historical rank and industry rank for Stayble Therapeutics AB's FCF Margin % or its related term are showing as below:

During the past 7 years, the highest FCF Margin % of Stayble Therapeutics AB was -14222.22%. The lowest was -14222.22%. And the median was -14222.22%.

OSTO:STABL's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Stayble Therapeutics AB FCF Margin % Historical Data

The historical data trend for Stayble Therapeutics AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB FCF Margin % Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

Stayble Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Stayble Therapeutics AB's FCF Margin %

For the Biotechnology subindustry, Stayble Therapeutics AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's FCF Margin % falls into.

Stayble Therapeutics AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Stayble Therapeutics AB's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-24.886	/	0
	=	%

Stayble Therapeutics AB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-4.464	/	0
	=	%

Stayble Therapeutics AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56

Website

https://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB Headlines

No Headlines